Pharmacy and Poisons Board

Clinical Trial Applications - Approved: Filter, Search, and view applications

Clear
Extended search...

Page 3 of 14, showing 10 Applications out of 131 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

21.

 ECCT/15/11/05   FALCI Study
    A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria.    		Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
1. KEMRI Center for Respiratory Diseases Research (Siaya county)
2. KEMRI Walter Reed Kombewa (Kisumu county)
3. KEMRI Kisumu (Kisumu county)
  		01-02-2016 View

22.

 ECCT/15/11/04   VAC040
    A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months)    		Principal Investigator(s)
1. John Anthony Gerard Scott
Site(s) in Kenya
KEMRI-Wellcome Trust Research Program
  		09-02-2016 View

23.

 ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]    		Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
  		15-04-2016 View

24.

 ECCT/16/02/05   PfSPZ Malaria Vaccine
    Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy    		Principal Investigator(s)
1. Martina Oneko
2. Mary J Hamel
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Wagai Health Center (Siaya county)
  		18-05-2016 View

25.

 ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants        		Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
  		03-06-2016 View

26.

 ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection    		Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
  		14-07-2016 View

27.

 ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study    		Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
  		25-07-2016 View

28.

 ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)    		Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
  		28-07-2016 View

29.

 ECCT/16/07/05   HESTIA 1
    Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease    		Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county)
3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county)
4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county)
  		19-09-2016 View

30.

 ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection    		Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
  		27-10-2016 View